Forte Biosciences 

€29.6
0
-€0.2-0.67% Today

Statistics

Day High
29.6
Day Low
27.8
52W High
29.8
52W Low
7.5
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 37T.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals competes in the development of biologic drugs for skin diseases, similar to Forte Biosciences' focus on dermatology.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie has a strong portfolio in dermatology, including treatments for conditions that Forte Biosciences targets.
AMGEN
AMGN
Mkt Cap187.56B
Amgen has a presence in the dermatology market, competing with Forte Biosciences in developing treatments for skin conditions.
Journey Medical
DERM
Mkt Cap164.62M
Journey Medical Corporation (formerly Dermira) focuses on dermatological conditions, directly competing with Forte Biosciences' dermatology focus.
AnaptysBio
ANAB
Mkt Cap1.66B
AnaptysBio is involved in developing therapeutic antibodies for inflammatory diseases, including dermatological conditions, making it a competitor.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, through its acquisition of Immunomedics, competes in the biopharmaceutical space with a focus on treatments that could overlap with Forte Biosciences' interests.
Merck
MRK
Mkt Cap298.84B
Merck & Co. has a diversified portfolio that includes treatments for skin diseases, competing with Forte Biosciences in the dermatology space.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a broad range of healthcare products, including those for dermatological conditions, making it a competitor to Forte Biosciences.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, offers products for dermatology, competing with Forte Biosciences.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb has a diverse biopharmaceutical portfolio that includes treatments for skin diseases, competing with Forte Biosciences.

About

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Show more...
CEO
Dr. Paul A. Wagner Ph.D.
Employees
16
Country
DE
ISIN
US34962G2084

Listings

0 Comments

Share your thoughts

FAQ

What is Forte Biosciences stock price today?
The current price of 37T.STU is €29.6 EUR — it has decreased by -0.67% in the past 24 hours. Watch Forte Biosciences stock price performance more closely on the chart.
What is Forte Biosciences stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Forte Biosciences stocks are traded under the ticker 37T.STU.
Is Forte Biosciences stock price growing?
37T.STU stock has risen by +34.55% compared to the previous week, the month change is a +23.33% rise, over the last year Forte Biosciences has showed a +294.67% increase.
How many employees does Forte Biosciences have?
As of April 10, 2026, the company has 16 employees.
When did Forte Biosciences complete a stock split?
Forte Biosciences has not had any recent stock splits.
Where is Forte Biosciences headquartered?
Forte Biosciences is headquartered in Dallas, DE.